Orthocell’s autologous tendon therapy is the most advanced injectable cellular therapy for the treatment of chronic tendon injuries. 

he patient’s own healthy tendon-derived cells are used to help regenerate damaged tendons, reducing pain and restoring function. The innovative therapy addresses a significant unmet clinical need for a safe, effective, and non-surgical solution. OrthoATI™ is not available for sale, distribution, or clinical use in the United States.

How It Works

Autologous tendon therapy is a two-stage procedure. A biopsy of healthy tendon, typically from the patella tendon, is performed in a doctor’s room using local anaesthetic. The biopsied tissue is sent to Orthocell’s quality-controlled laboratory, where the cellular building blocks of the tendon, the tenocytes, are isolated and grown to a clinically significant number under controlled conditions. Finally, the tendon cells are implanted into the affected tendon approximately 4–5 weeks after the initial biopsy, via an ultrasound-guided injection under local anaesthetic.